HCA Health Inc vs Procter & Gamble Co — how do they compare? HCA Health Inc trades at $411.81 (market cap $89.64B), while Procter & Gamble Co trades at $146.14 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 3.8× HCA Health Inc's market cap, and Procter & Gamble Co pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| HCA | PG | |
|---|---|---|
Market Cap | $89.64B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $545.13 | $167.18 |
52-Week Low | $361.32 | $138.10 |
Enterprise Value | $140.18B | $366.23B |
Dividend Yield | 0.75% | 2.97% |
Volume | — | 6,423,436 |
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $413.36, up 1.09% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $449.93. The company reported strong Q2 2026 earnings of $7.59 per share, beating estimates, and has shown consistent revenue growth, reaching $75.60 billion in 2025. Recent corporate actions include dividend payments of $0.78 per share, while news highlights executive appointments and ongoing legal investigations.
The stock presents a compelling investment case with attractive valuation multiples like a P/E of 13.86 and robust profitability, but faces risks from legal probes and high debt levels. Upside potential is supported by analyst optimism and solid operational cash flow, though investors should monitor expense pressures and regulatory developments.
Procter & Gamble (PG) trades at $145.21, down 0.38% on the day, with a bearish technical signal from moving averages. The company maintains strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.43 beating expectations of $1.41. Revenue reached $84.28 billion in 2025 with net income of $15.97 billion, supported by a robust 18.44% net margin and 30.13% ROE. Recent developments include a new WNBA partnership and a $1.09 dividend declaration for August 2026 payment.
PG offers stable dividend income with 69 consecutive years of increases, but faces premium valuation concerns at 22.12 P/E ratio. Analyst consensus targets $161.20 with 53% buy ratings, suggesting 11% upside potential. Key risks include soft demand outlook and elevated valuation multiples compared to peers. The stock presents a defensive investment opportunity amid market volatility, though near-term growth appears modest.
Trailing returns across standard periods
Latest headlines on both assets
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →